GF CSI Innovative Drugs Industry ETF (515120) Rises Over 1% in Morning Trading, Aiming for Third Consecutive Gain

As of 10:31 on January 7, 2026, Innovation Drug ETF (515120) rose 1.07%, aiming for its third consecutive gain, with the latest price at 0.66 yuan. Over a longer timeframe, as of January 6, 2026, the ETF has accumulated a gain of 2.03% over the past two weeks, ranking 3rd out of 7 comparable funds. (The stocks listed above are index constituents only and do not constitute specific recommendations.)

In terms of liquidity, Innovation Drug ETF recorded an intraday turnover rate of 3.04% and trading volume of 234 million yuan. Over a longer period, as of January 6, its average daily trading volume reached 351 million yuan over the past week, ranking among the top 2 comparable funds.

Scale-wise, Innovation Drug ETF's size grew 342 million yuan over the past two weeks, achieving significant growth and ranking 1st out of 7 comparable funds in new scale increase. (Data source: Wind)

In terms of shares outstanding, the ETF's share count grew 321 million units over the past two weeks, achieving significant growth and ranking 1st out of 7 comparable funds in new share increase. (Data source: Wind)

Regarding capital flows, Innovation Drug ETF posted a latest net capital inflow of 151 million yuan. Over a longer timeframe, it saw net inflows on 5 of the past 8 trading days, totaling 90.0937 million yuan in "capital absorption," with an average daily net inflow of 11.2617 million yuan. (Data source: Wind)

Data shows leveraged funds continue to build positions. Innovation Drug ETF's previous day net margin purchase reached 14.3805 million yuan, with the latest margin balance at 321 million yuan. (Data source: Wind)

As of January 6, Innovation Drug ETF's NAV rose 28.65% over the past year. In terms of return capability, as of January 6, 2026, since its inception, the ETF's highest monthly return was 23.00%, longest consecutive up months was 5, longest consecutive gain was 32.68%, and average return in up months was 5.83%. As of January 6, 2026, its two-year excess return over benchmark reached 0.80% annualized.

On drawdowns, as of January 6, 2026, Innovation Drug ETF's year-to-date maximum drawdown was 0.00%, with a relative benchmark drawdown of 0.01%.

In terms of fees, Innovation Drug ETF charges a management fee of 0.50% and a custody fee of 0.10%.

Regarding tracking accuracy, as of January 6, 2026, Innovation Drug ETF's two-month tracking error was 0.011%, the highest tracking precision among comparable funds.

Innovation Drug ETF closely tracks the CSI Innovation Drug Industry Index, which selects up to 50 most representative listed securities from companies whose main business involves innovation drug R&D as index samples to reflect the overall performance of the innovation drug industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.